

Prostate cancer screening: the Stockholm3 test improves detection by 22% and reduces biopsy requirements by 76%

- *The Stockholm3 blood test analyzes five protein markers, over 100 genetic markers, and clinical data, enhancing diagnostic precision of prostate cancer, enabling early detection of high-risk cases, and significantly reducing unnecessary biopsies.*
- *With data from nearly 60,000 men—the largest dataset of its kind—Stockholm3 is setting a new standard in prostate cancer diagnosis, improving both recovery rates and patients' quality of life.*
- *Wiener Privatlinik (WPK) is currently the only hospital in Austria—and one of the few in Europe—where Romanian patients can access this advanced diagnostic option alongside conventional PSA testing.*

Bucharest, (date): The Stockholm3 test, based on data from nearly 60,000 men — the largest dataset of its kind — sets a new standard in prostate cancer diagnosis, boosting cure rates and enhancing patient quality of life. Professor Dr. Georg Schatzl, internationally renowned specialist in urology and andrology offers this innovative test at Wiener Privatlinik, currently the only facility in Austria and one of the few in Europe with this advanced diagnostic option.

Wiener Privatlinik, one of Austria's largest private hospitals and certified among the *World's Best Hospitals*, is setting a new benchmark in prostate cancer screening and diagnosis with the innovative Stockholm3 blood test. This revolutionary test significantly increases prostate cancer detection rates while drastically reducing the need for invasive biopsies.

Prostate cancer is the leading cancer diagnosis among Romanian men, with over 10,000 new cases each year, representing 18% of all male cancer diagnoses¹. By 2040, incidence rates are projected to rise by nearly 22%², highlighting an urgent need for accurate and early diagnostic solutions to improve patient outcomes and manage the growing healthcare impact.

Limitations of conventional PSA testing

¹ <https://gco.iarc.who.int/today/en/dataviz/pie?mode=cancer&types=0&sexes=1&populations=642>

² <https://insp.gov.ro/wp-content/uploads/2024/03/Profil-de-tara-privind-cancerul-2023.pdf>

The PSA (Prostate-Specific Antigen) test, while widely used in prostate cancer screening and diagnosis, has significant limitations. One major drawback is its tendency to produce false positives, leading to unnecessary invasive biopsies that not only heighten anxiety but also expose patients to potential side effects. On the other hand, the PSA test can yield false negatives that result in missed diagnoses, particularly in cases involving more aggressive prostate cancers, where early detection is crucial for effective treatment.

Stockholm3 test, a new benchmark in prostate cancer screening

The Stockholm3 test is an advanced screening tool that goes beyond measuring prostate-specific antigen levels by analyzing five protein markers, over 100 genetic markers, and clinical data such as age and family history. This comprehensive approach provides higher diagnostic precision and allows early identification of high-risk patients.

Univ. Prof. Dr. Christoph Zielinski, Medical Director of Wiener Privatklinik and Professor of Medical Oncology and Clinical Immunology, explains: *‘The Stockholm3 test represents a significant advancement in predicting prostate cancer risk. This accuracy not only empowers at-risk patients to take preventive measures but also reduces healthcare costs.’*

Clinical studies have shown that the Stockholm3 test increases prostate cancer detection rates by 22% and reduces biopsy requirements by up to 76%.

Univ. Prof. Dr. Georg Schatzl, urology and andrology specialist at Wiener Privatklinik, emphasizes the clinical impact: *‘This innovative blood test improves our ability to detect aggressive prostate carcinomas earlier than conventional PSA tests, allowing timely and effective treatments that enhance patient cure rates and quality of life.’*

Advanced diagnostic and treatment solutions available in Vienna

At Wiener Privatklinik in Vienna, Romanian patients have access to comprehensive and advanced solutions for prostate cancer screening, diagnosis, and treatment. If the Stockholm3 test suggests a malignancy risk, a multiparametric MRI is conducted for risk assessment. Based on MRI findings, a biopsy may be performed using state-of-the-art fusion techniques that combine MRI and ultrasound images for greater precision.

For confirmed prostate cancer cases, Wiener Privatklinik offers personalized treatment options tailored to the patient's health profile. These include surgical options such as the robot-assisted Da Vinci technology, which enables precise, minimally invasive procedures that protect surrounding nerves and blood vessels. Additionally, other therapeutic options such as radiotherapy and brachytherapy are available.



About Wiener Privatklinik

Founded in 1871 in Vienna, Wiener Privatklinik is one of Austria's largest private hospitals and holds the *World's Best Hospitals* certification (2021 – 2024). Wiener Privatklinik provides medical services across more than 30 specialties, featuring 10 competence centers, 145 beds, a surgical department with 4 operating rooms, and a radiology center equipped with PET-CT and nuclear medicine. The hospital is also home to the only private radiotherapy center in Austria, inaugurated in 2020. Patients have access to over 300 internationally renowned medical experts employing the latest diagnostic methods and state-of-the-art treatments.